Results from a recent study indicate that adalimumab, manufactured under the trade name Humira, showed an improvement of symptoms in patients with psoriasis. Among patients receiving 40 mg of adalimumab every other week, more than 50% reported an improvement of 75% or more in their symptoms, whereas 80% of the patients receiving the 40-mg dose every week reported a 75% improvement. Statistically significant results were achieved after 12 weeks, and some patients reported a significant level of improvement after only 4 weeks. At 12 weeks, 49% of patients taking the 40-mg every-other-week dosage and 76% of patients taking the 40-mg weekly dosage reported that they were "clear" or "almost clear" of their disease activity, as measured by the Physician's Global Assessment.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs